Project summary:

OCTAVE DUO, an extension of the OCTAVE trial, is investigating if a third vaccine dose for people with weakened immune systems gives a stronger immune response than two doses.

Up to 1,200 patients who are already involved in the OCTAVE study or who have other at-risk conditions in parallel studies will be recruited. These include patients who had a low or absent immune response after two doses of vaccine (Oxford/AstraZeneca or Pfizer). They will be given a third booster (of Pfizer, Moderna or Novavax) to see whether this will give them sufficient protection.

The study will analyse in detail their immune response to the vaccine and the durability of this response. They will also use health care records to determine whether any participants are subsequently diagnosed with SARS-CoV-2.

Patient cohorts included in the study are people with:

  • lymphoid malignancies
  • immune mediated inflammatory diseases (including rheumatoid arthritis, psoriatic arthritis, vasculitis and inflammatory bowel disease)
  • renal disease
  • solid tumours (including breast and lung cancers)
  • haematopoietic stem-cell transplantation
  • hepatic and intestinal disease
  • primary immune deficiency

Vavada Casino's 4500+ slots offer endless thrills, all verified by a Curacao license. Place your bets and let fortune smile upon you.


National Institute for Health Research (NIHR), UK Research and Innovation (UKRI)

Leader researcher:

Professor Iain McInnes

Lead institution:

University of Glasgow

Vaccine type: